Table 4.
Hazard ratios for cause-specific mortality for women with incident RA by serologic phenotype compared to women without RA in the Nurses’ Health Study (1976–2012)*
| Cancer mortality
|
Cardiovascular mortality
|
Respiratory mortality
|
||||
|---|---|---|---|---|---|---|
| Age-adjusted HR (95% CI) | Multivariable HR (95% CI)† | Age-adjusted HR (95% CI) | Multivariable HR (95% CI)† | Age-adjusted HR (95% CI) | Multivariable HR (95% CI)† | |
| All RA | ||||||
| No RA | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| RA | 1.00 (0.80–1.25) | 0.93 (0.74–1.15) | 1.49 (1.18–1.89) | 1.45 (1.14–1.83) | 2.57 (1.91–3.48) | 2.06 (1.51–2.80) |
| Seropositive RA | ||||||
| No RA | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| RA | 0.95 (0.71–1.26) | 0.86 (0.65–1.15) | 1.39 (1.02–1.90) | 1.41 (1.03–1.93) | 3.55 (2.55–4.95) | 2.67 (1.89–3.77) |
| Seronegative RA | ||||||
| No RA | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) | 1.00 (reference) |
| RA | 1.01 (0.72–1.42) | 0.96 (0.68–1.35) | 1.55 (1.08–2.21) | 1.41 (0.98–2.02) | 1.09 (0.54–2.19) | 0.98 (0.49–1.99) |
RA = rheumatoid arthritis; HR = hazard ratio; 95% CI = 95% confidence interval.
Model adjusted for age, questionnaire cycle, census-tract family income (<$40,000 or ≥$40,000 per year), body mass index (<18.5, 18.5–24.9, 25–29.9, or ≥30 kg/m2), cigarette smoking (never–10, 10.1–20, or >20 pack-years), postmenopausal hormone use (premenopausal, postmenopausal: never postmenopausal hormone use, postmenopausal: past postmenopausal hormone use, or postmenopausal: current postmenopausal hormone use), moderate to vigorous physical activity (0, 0.01–0.99, 1.00–3.49, 3.50–5.99, or ≥6 hours per week), cumulative average of Alternate Healthy Eating Index excluding alcohol component (quintiles), alcohol consumption (0, 0.1–4.9, 5.0–14.9, or ≥15.0 gm/day), cardiovascular disease (yes/ no), and aspirin use (yes/no). Covariates were updated up to death, end of study period, censor, or loss to follow-up, whichever came first.